Table 2.
Clinical characteristics of the patients
| TM + TE (two-stage IBBR) |
NSM + TE (two-stage IBBR) |
NSM + direct-to-implant (one-stage IBBR) |
|
|---|---|---|---|
| No. of patients | 37 | 18 | 16 |
| Median age, yrs (range) | 49 (35–76) | 47 (30–61) | 50 (42–74) |
| Pathological stage (%) | |||
| Stage 0 (DCIS/LCIS) cases | 5 (13.5) | 8 (44.4) | 4 (25) |
| Stage I cases | 22 (59.5) | 8 (44.4) | 6 (37.5) |
| Stage II cases | 10 (27) | 2 (11.2) | 6 (37.5) |
| Biologic subtype (%) | |||
| Luminal cases | 27 (72.9) | 15 (83.2) | 14 (87.5) |
| HER2-positive cases | 8 (21.6) | 2 (11.2) | 1 (6.25) |
| Triple-negative cases | 2 (5.5) | 1 (5.6) | 1 (6.25) |
| Operation time, mean | 236.0 min. | 247.2 min. | 321.0 min. |
| Sentinel lymph node biopsy (%) | 31 (83.8) | 13 (72.2) | 14 (87.5) |
| Axillary lymph node dissection* (%) | 4 (10.8) | 4 (22.2) | 2 (11.8) |
| Blood loss, mean ml | 60.4 | 88.8 | 138.0 |
| Hospitalization, mean days | 16.7 | 15.2 | 14.0 |
| Chemotherapy (%) | 16 (43.2) | 8 (44.4) | 6 (37.5) |
| Neoadjuvant/adjuvant | (2/14) | (1/7) | (1/6) |
| Adjuvant endocrine therapy (%) | 26 (70.3) | 11 (61.1) | 7 (43.8) |
TM: total mastectomy including skin-sparing mastectomy (SSM); NSM: nipple-sparing mastectomy; TE: tissue expander; IBBR: implant based breast reconstruction
*All cases: pN1a